Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - rivastigmine -

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - buprenorphine -

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - 44237 - lubricant, eye - drops to improve lubrication of the eye surface in eyes that are severely dry and irritated from external factors. they are supplied in a double walled dropper bottle with an airless pump that delivers one drop of product per actuation of the pump. to improve the lubrication of the eye in eyes that are experiencing severe or persistent dryness

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

akzo nobel pty limited - cuprous oxide; diuron - paint - cuprous oxide mineral-copper active 525.0 g/l; diuron urea-substituted active 45.0 g/l - antifouling - boat - exterior (antifouling) - fouling - for antifouling on boats

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine 18mg;  ;   - transdermal patch - 9.5 mg/24h - active: rivastigmine 18mg     excipient: dimeticone dl-alpha tocopherol acrylic pressure sensitive adhesive silicone pressure sensitive adhesive backing film 10 cm square release liner 20.25 cm square poly(butyl methacrylate-co-methyl methacrylate) - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine 27mg;  ;   - transdermal patch - 13.3 mg/24h - active: rivastigmine 27mg     excipient: dimeticone dl-alpha tocopherol acrylic pressure sensitive adhesive silicone pressure sensitive adhesive backing film 15 cm square release liner 30.375 cm square poly(butyl methacrylate-co-methyl methacrylate) - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine 36mg;  ;   - transdermal patch - 17.4 mg/24h - active: rivastigmine 36mg     excipient: dimeticone dl-alpha tocopherol acrylic pressure sensitive adhesive silicone pressure sensitive adhesive backing film 20 cm square release liner 40.5 cm square poly(butyl methacrylate-co-methyl methacrylate) - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine 9mg;  ;   - transdermal patch - 4.6 mg/24h - active: rivastigmine 9mg     excipient: dimeticone dl-alpha tocopherol acrylic pressure sensitive adhesive silicone pressure sensitive adhesive backing film 5 cm square release liner 10.125 cm square poly(butyl methacrylate-co-methyl methacrylate) - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.

New Zealand - English - Medsafe (Medicines Safety Authority)

johnson & johnson (new zealand) limited - nicotine 8.3mg (10cm² patch delivers 5mg/16hours.);   - transdermal patch - 5mg/16hours - active: nicotine 8.3mg (10cm² patch delivers 5mg/16hours.)  

New Zealand - English - Medsafe (Medicines Safety Authority)

johnson & johnson (new zealand) limited - nicotine 8.3mg (as a 10cm² patch delivering 5mg/16hours);   - transdermal patch - 0.31 mg/h - active: nicotine 8.3mg (as a 10cm² patch delivering 5mg/16hours)